ALLMedicine™ Chronic Lymphocytic Leukemia Center
Research & Reviews 5,787 results
https://www.mdedge.com/hematology-oncology/article/255835/cll/superior-cll-regimen-cuts-chemo-half
Nancy A. Melville
Jun 28th, 2022 - VIENNA – Ibrutinib and obinutuzumab combined with a three-cycle regimen of chemotherapy as a first-line treatment for fit patients with chronic lymphocytic leukemia (CLL) shows progression-free and overall survival rates that are comparable, if no.
https://doi.org/10.1111/jth.15802
Journal of Thrombosis and Haemostasis : JTH; Taparia K, Wall E et. al.
Jun 26th, 2022 - The diagnosis of immune thrombocytopenia (ITP) is one of exclusion. While guidelines recommend against routine bone marrow examination (BME) at time of ITP diagnosis, the role of BME in relapsed/refractory ITP is unclear. To examine the frequency ...
https://doi.org/10.1038/s41375-022-01629-7 10.2217/fon-2017-0442 10.1182/asheducation-2013.1.138 10.1038/s41375-018-0313-8 10.1182/blood-2017-09-806398 10.1056/NEJMoa1509388 10.1182/blood-2014-10-606038 10.1056/NEJMoa1815281 10.1056/NEJMoa1713976 10.1016/S1470-2045(18)30788-5
Leukemia von Tresckow J, Cramer P et. al.
Jun 26th, 2022 - Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.|2022|von Tresckow J,Cramer P,Robrecht S,Langerbeins P,Fink AM,|
https://clinicaltrials.gov/ct2/show/NCT01087294
Jun 24th, 2022 - Background: Many patients with advanced B-cell malignancies that cannot be cured by chemotherapy and monoclonal antibodies have prolonged relapse-free survival after allogeneic hematopoietic stem cell transplantation (alloHSCT); however, a substan...
https://clinicaltrials.gov/ct2/show/NCT01139476
Jun 24th, 2022 - We propose to conduct a molecular epidemiology study with a subset of participants in the Agricultural Health Study (AHS), a prospective cohort of 57,310 licensed pesticide applicators in Iowa and North Carolina. Blood and urine samples will be co...
Guidelines 9 results
https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-voluntary-withdrawal-blasnda-u2-treat
TG Therapeutics
Apr 15th, 2022 - NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Company has voluntarily withdrawn the pending Biologics License Application (BLA)/supplemental New Drug Application (sNDA) for the combinat...
https://doi.org/10.6004/jnccn.2020.0006
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.
Feb 6th, 2020 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940638
Leukemia Malcikova J, Tausch E et. al.
Feb 23rd, 2018 - In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. On these grounds...
https://doi.org/10.6004/jnccn.2017.0030
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Zelenetz AD et. al.
Mar 10th, 2017 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmu...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841457
Journal of the National Comprehensive Cancer Network : JN... Zelenetz AD, Gordon LI et. al.
Mar 5th, 2015 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the develop...
Drugs 47 results see all →
Clinicaltrials.gov 906 results
https://clinicaltrials.gov/ct2/show/NCT04030195
Jun 24th, 2022 - This is a multicenter, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate safety, tolerability, clinical activity, and find an appropriate dose to optimize safety and efficacy of PBCA...
https://clinicaltrials.gov/ct2/show/NCT03204188
Jun 24th, 2022 - Background: This study investigates the combination of ibrutinib, fludarabine and pembrolizumab for treatment of CLL. Chronic lymphocytic leukemia and small lymphocytic lymphoma (hereby referred as CLL) are tumors of B cells. A subset of patients ...
https://clinicaltrials.gov/ct2/show/NCT04269902
Jun 24th, 2022 - PRIMARY OBJECTIVE: I. To evaluate whether early treatment with venetoclax and obinutuzumab (V-O) extends overall survival (OS) compared with delayed treatment with V-O in high-risk (Chronic Lymphocytic Leukemia [CLL] International Prognostic Indic...
https://clinicaltrials.gov/ct2/show/NCT04102423
Jun 24th, 2022 - Clonal Hematopoiesis of Indeterminate Potential (CHIP) has been defined as the presence of a somatic pathogenic variant associated with hematological malignancy, with an allele fraction of at least 2%, without morphological evidence of bone marrow...
https://clinicaltrials.gov/ct2/show/NCT01139476
Jun 24th, 2022 - We propose to conduct a molecular epidemiology study with a subset of participants in the Agricultural Health Study (AHS), a prospective cohort of 57,310 licensed pesticide applicators in Iowa and North Carolina. Blood and urine samples will be co...
News 1,692 results
https://www.mdedge.com/hematology-oncology/article/255835/cll/superior-cll-regimen-cuts-chemo-half
Nancy A. Melville
Jun 28th, 2022 - VIENNA – Ibrutinib and obinutuzumab combined with a three-cycle regimen of chemotherapy as a first-line treatment for fit patients with chronic lymphocytic leukemia (CLL) shows progression-free and overall survival rates that are comparable, if no.
https://www.medscape.com/viewarticle/975652
Jun 15th, 2022 - Use of the targeted therapy combination of venetoclax plus obinutuzumab for fit patients with chronic lymphocytic leukemia (CLL) significantly improved progression-free survival (PFS) at 3 years compared with standard chemoimmunotherapy, new phase...
https://www.medscape.com/viewarticle/974875
Jun 1st, 2022 - Today, the US Food and Drug Administration (FDA) announced it has withdrawn approval of the lymphoma drug umbralisib (Ukoniq) following an investigation into a "possible increased risk of death." Umbralisib had received accelerated approval in Feb...
https://www.mdedge.com/hematology-oncology/article/254888/cll/phase-3-study-leukemia-patients-live-longer-ibrutinib
Heidi Splete
May 24th, 2022 - Chronic lymphocytic leukemia (CLL) patients aged 65 years and older who were treated with ibrutinib showed sustained progression-free and overall survival benefits up to 8 years later, based on follow-up data from the RESONATE-2 trial. “This trial.
https://www.medscape.com/viewarticle/974234
May 18th, 2022 - Patients receiving treatment with ibrutinib for chronic lymphocytic leukemia (CLL) show significant increases in the risk for bleeding when undergoing Mohs micrographic surgery for skin cancer, indicating the need for temporary treatment interrupt...